The Investor Relations Podcast
Podcast Description: The Investor Relations Podcast
Joshua Wilson is a registered investment banking representative and a licensed real estate broker. The content of this podcast is for informational purposes only and should not be considered legal, financial, or compliance advice. This podcast is not a substitute for professional advice. All views and opinions expressed by the host and guests are their own and do not necessarily reflect the policies or positions of any regulatory agency, organization, or employer. Listeners are encouraged to consult their own compliance teams, legal counsel, or financial advisors to ensure adherence to applicable regulations, including SEC, FINRA, and other industry-specific requirements. This podcast does not constitute a solicitation or recommendation for any financial products or services.
Welcome to The Investor Relations Podcast, where we explore the complex and fascinating world of capital markets, regulatory compliance, and investor communication. This show is designed for Investor Relations professionals, registered investment bankers, financial advisors, and corporate executives who want to sharpen their skills, stay informed, and navigate today’s fast-paced financial environment with confidence.
Each episode features industry leaders sharing actionable insights and experiences on topics critical to investor relations, including:
•Learn about the details of IPOs, secondary offerings, and PIPEs.
•Best practices for roadshows and crafting investor presentations that comply with SEC regulations.
•How to engage with retail and institutional investors while adhering to Reg FD.
•The role of social media in investor relations: What’s permissible, and where to tread carefully.
•Key strategies for handling earnings calls, forward-looking statements, and material disclosures.
•Managing shareholder activism and navigating the challenges of modern corporate governance.
•Reporting: How to communicate environmental, social, and governance efforts effectively.
Why Listen?
Whether you’re preparing for a capital raise, leading communications for a public company, or ensuring your team remains compliant, this show provides real-world conversations and valuable connections to help you succeed.
Ideal Guest: Are you a professional managing investor relations for a public company, guiding a team through an IPO, or helping corporations navigate compliance in a highly regulated environment? If so, we’d love to feature your expertise. This is an opportunity to showcase your knowledge, expand your professional network, and contribute to the broader conversation around transparency and trust in capital markets.
What’s In It for You?
•Gain actionable strategies for engaging and communicating with investors.
•Understand the nuances of SEC compliance, Reg FD, and FINRA rules.
•Learn how to build investor trust and drive long-term shareholder value.
•Get behind-the-scenes insights into successful capital raises, IPOs, and secondary offerings.
•Be part of a community of professionals dedicated to improving transparency and effectiveness in investor relations.
Whether you’re an IR professional, investment banker, or financial advisor, The Investor Relations Podcast delivers the insights, strategies, and connections you need to excel in the world of capital markets.
Subscribe now and be part of the conversation shaping the future of investor relations. If you’re interested in being a guest, send us a direct message to share your expertise and join our growing network of professionals.
The Investor Relations Podcast
IR Strategies Around Clinical Trial Success
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
In this episode of The Investor Relations Podcast, Michael Loftus, Biotech Growth Architect and Family Office Strategist, shares how biotech companies should approach investor relations conversations around major clinical milestones. He explains why early and proactive engagement is critical, what types of conversations to prioritize before and after approval, and how the current market environment has shifted expectations compared to previous years.
The discussion highlights the importance of realistic revenue communication, the risks of overselling financial expectations, and the need for transparency to build trust. Michael emphasizes why biotechs should be talking with investors well before the final approval decision to avoid falling behind and to establish long-term credibility.
#InvestorRelations #Biotech #LifeSciences #CapitalMarkets #ClinicalTrials #BiotechInvesting
Connect with the Guest
- Company: https://www.poccap.com
- LinkedIn: https://www.linkedin.com/in/mikeloftusclinicaltrials/
- Podcast profile: View all of their episodes here
Connect with the Host
- Joshua Wilson LinkedIn: https://www.linkedin.com/in/joshuabrucewilson/
- The Investor Relations Podcast YouTube channel: https://www.youtube.com/@TheInvestorRelationsPodcast
Contact Link
https://www.theinvestorrelationspodcast.com/contact/
Disclaimer: Joshua Wilson is a licensed Florida real estate broker and holds FINRA Series 79 and Series 63 licensure. The content of this podcast is for informational and educational purposes only and should not be considered legal, financial, or compliance advice. All views and opinions expressed by the host and guests are their own and do not necessarily reflect the policies or positions of any regulatory agency, organization, or employer. Listeners should consult their own legal counsel, compliance teams, or financial advisors to ensure adherence to applicable regulations, including SEC, FINRA, and other industry-specific requirements. This podcast does not constitute a solicitation or recommendation for any financial products or services.
Let’s Connect on LinkedIn:
https://www.linkedin.com/in/joshuabrucewilson/
To Contact Us, Please Visit:
Joshua:
So Michael, a biotech company goes through the different clinical trials and then they have the last one and it worked, right? What are some of the conversations that you want to have with investors, maybe right before that and maybe afterwards?
Michael Loftus:
Well, you’ve got to assess the options in the market. There’s a lot going on, and the market today is a little different than it was five years ago. A company that has an approved asset—or almost approved asset—would have had different conversations then versus now. Really now, it’s about revenue: how much revenue you think you’ll be able to generate in that first one to five years, and what markets it will cover. Is it a worldwide asset, or is it country by country?
Some of the things I’ve seen go wrong in the past are when a company oversells the revenue that’s going to happen. That might get people interested quickly, but it can also cause them to exit later on. I think being open and honest, especially in today’s market, will give you your best chance for long-term success.
As far as talking to people, talk early. Get out there and build those relationships now, because if the drug is approved, you may already be six months behind if you haven’t been out there communicating with the world.
